Home/Filings/3/0000950170-24-035939
3//SEC Filing

Versant Venture Capital VII, L.P. 3

Accession 0000950170-24-035939

CIK 0001815776other

Filed

Mar 24, 8:00 PM ET

Accepted

Mar 25, 4:19 PM ET

Size

9.7 KB

Accession

0000950170-24-035939

Insider Transaction Report

Form 3
Period: 2024-03-21
Holdings
  • Warrant (Right to Buy)

    Exercise: $10.64From: 2024-03-21Exp: 2027-10-30Common Stock (70,534 underlying)
  • Common Stock

    1,598,789
Holdings
  • Warrant (Right to Buy)

    Exercise: $10.64From: 2024-03-21Exp: 2027-10-30Common Stock (70,534 underlying)
  • Common Stock

    1,598,789
Holdings
  • Warrant (Right to Buy)

    Exercise: $10.64From: 2024-03-21Exp: 2027-10-30Common Stock (70,534 underlying)
  • Common Stock

    1,598,789
Footnotes (2)
  • [F1]These securities were acquired pursuant to that certain Agreement and Plan of Merger by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), and Lenz Therapeutics, Inc., a Delaware corporation ("LENZ"), pursuant to which the Merger Sub merged with and into LENZ (the "Merger"), with LENZ continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the Merger.
  • [F2]These securities are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII disclaims beneficial ownership of the shares held by VVC VII, except to the extent of their respective pecuniary interests therein.

Documents

1 file

Issuer

LENZ Therapeutics, Inc.

CIK 0001815776

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001750266

Filing Metadata

Form type
3
Filed
Mar 24, 8:00 PM ET
Accepted
Mar 25, 4:19 PM ET
Size
9.7 KB